BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vo KP, Vutien P, Akiyama MJ, Vu VD, Ha NB, Piotrowski JI, Wantuck J, Roytman MM, Tsai N, Cheung R, Li J, Nguyen MH. Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir. Dig Dis Sci 2015;60:1045-51. [DOI: 10.1007/s10620-015-3621-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Younossi ZM, Tanaka A, Eguchi Y, Lim YS, Yu ML, Kawada N, Dan YY, Brooks-Rooney C, Negro F, Mondelli MU. The impact of hepatitis C virus outside the liver: Evidence from Asia. Liver Int. 2017;37:159-172. [PMID: 27748564 DOI: 10.1111/liv.13272] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
2 Campos Fernández de Sevilla MÁ, Gallego Úbeda M, Tovar Pozo M, García-Cabrera E, Monje García B, Tutau Gómez F, Delgado Téllez de Cepeda L, Iglesias-Peinado I. Measure of adherence to direct-acting antivirals as a predictor of the effectiveness of hepatitis C treatment. Int J Clin Pharm 2019;41:1545-54. [PMID: 31650508 DOI: 10.1007/s11096-019-00917-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Chachá SGF, Rodrigues JPV, Araújo RC, Pereira LRL, Villanova MG, Souza FF, Santana RC, Martinelli ALC. First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients. Rev Soc Bras Med Trop 2018;51:146-54. [PMID: 29768546 DOI: 10.1590/0037-8682-0153-2017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Vutien P, Hoang J, Brooks L Jr, Nguyen NH, Nguyen MH. Racial Disparities in Treatment Rates for Chronic Hepatitis C: Analysis of a Population-Based Cohort of 73,665 Patients in the United States. Medicine (Baltimore) 2016;95:e3719. [PMID: 27258498 DOI: 10.1097/MD.0000000000003719] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 5.2] [Reference Citation Analysis]
5 Burstow NJ, Mohamed Z, Gomaa AI, Sonderup MW, Cook NA, Waked I, Spearman CW, Taylor-Robinson SD. Hepatitis C treatment: where are we now? Int J Gen Med 2017;10:39-52. [PMID: 28255252 DOI: 10.2147/IJGM.S127689] [Cited by in F6Publishing: 21] [Reference Citation Analysis]
6 Callefi LA, Villela-Nogueira CA, de Barros Tenore S, Carnaúba-Júnior D, Coelho HSM, Pinto PTA, Nabuco LC, Pessoa MG, Ferraz MLCG, Ferreira PRA, de Lourdes Candolo Martinelli A, Chachá SGF, de Souza Paiva Ferreira A, de Macedo Bisio AP, Brandão-Mello CE, Álvares-Da-Silva MR, Reuter T, Ivantes CAP, de Mello Perez R, Mendes-Correa MCJ. Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study. Clinics (Sao Paulo) 2017;72:378-85. [PMID: 28658438 DOI: 10.6061/clinics/2017(06)08] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
7 Bichoupan K, Tandon N, Crismale JF, Hartman J, Del Bello D, Patel N, Chekuri S, Harty A, Ng M, Sigel KM, Bansal MB, Grewal P, Chang CY, Leong J, Im GY, Liu LU, Odin JA, Bach N, Friedman SL, Schiano TD, Perumalswami PV, Dieterich DT, Branch AD. Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results. World J Virol 2017; 6(4): 59-72 [PMID: 29147645 DOI: 10.5501/wjv.v6.i4.59] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Nguyen NH, Nguyen MH. Current Treatment Options in Patients with Hepatitis C Virus Genotype 6. Gastroenterol Clin North Am 2015;44:871-81. [PMID: 26600225 DOI: 10.1016/j.gtc.2015.07.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
9 Butt AA, Yan P, Shaikh OS, Chung RT, Sherman KE; ERCHIVES study. Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES. Liver Int 2016;36:1275-83. [PMID: 26928927 DOI: 10.1111/liv.13103] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
10 Deng L, Wang XH. Progress in antiviral treatment of chronic hepatitis C virus genotype 1 infection. Shijie Huaren Xiaohua Zazhi 2015; 23(27): 4368-4375 [DOI: 10.11569/wcjd.v23.i27.4368] [Reference Citation Analysis]
11 Roytman M, Ramkissoon R, Wu C, Hong L, Trujillo R, Huddleston L, Poerzgen P, Seto T, Wong L, Tsai N. Examining the clinical course of genotype 1 chronic hepatitis C patients treated with the cosmos regimen: including patients with advanced liver disease and East Asian ancestry. Hepatol Int 2016;10:616-23. [PMID: 27026431 DOI: 10.1007/s12072-016-9719-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
12 Nicolini LA, Menzaghi B, Ricci E, Martinelli C, Magni C, Maggi P, Celesia BM, Parruti G, Babudieri S, Bonfanti P, Falasca K, Vichi F, De Socio GV, Salomoni E, Di Biagio A, Quirino T. Effectiveness of first-generation HCV protease inhibitors: does HIV coinfection still play a role? Eur J Gastroenterol Hepatol 2016;28:37-41. [PMID: 26460621 DOI: 10.1097/MEG.0000000000000483] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
13 Gagné M, Têtu I, Grégoire J, Moisan J. Adherence and sustained virologic response among vulnerable people initiating an hepatitis C treatment at a nurse-led clinic: A non-experimental prospective cohort study based on clinical records. International Journal of Nursing Studies Advances 2021;3:100029. [DOI: 10.1016/j.ijnsa.2021.100029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Piekarska A, Koślińska-Berkan E, Wójcik K, Skubała A, Jabłkowski M, Deroń Z, Berkan-Kawińska A. Efficacy and direct costs of chronic hepatitis C treatment with first generation NS3/4A protease inhibitors in a real life population. Clin Exp Hepatol 2016;2:133-7. [PMID: 28856277 DOI: 10.5114/ceh.2016.63869] [Reference Citation Analysis]
15 Stahmeyer JT, Rossol S, Bert F, Böker KH, Bruch HR, Eisenbach C, Link R, John C, Mauss S, Heyne R, Schott E, Pfeiffer-Vornkahl H, Hüppe D, Krauth C. Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study. PLoS One 2016;11:e0159976. [PMID: 27467772 DOI: 10.1371/journal.pone.0159976] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
16 Rodrigues JPV, Cazarim MS, Chachá SGF, Martinelli ALC, Pereira LRL. Cost-effectiveness analysis is a mandatory strategy for health systems: evidence from a study involving therapies for hepatitis C. Cad Saude Publica 2020;36:e00036619. [PMID: 32022174 DOI: 10.1590/0102-311X00036619] [Reference Citation Analysis]
17 Gray E, Norris S, Schmitz S, O'Leary A. Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes? J Comp Eff Res 2017;6:65-82. [PMID: 27854129 DOI: 10.2217/cer-2016-0042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]